Just – Evotec Biologics has built a highly automated, state-of-the-art cGMP manufacturing facility, J.POD®. It uses an intensified, continuous process platform that connects high-performance, perfusion cell culture with intensified downstream processing.
J.POD can operate clinical or commercial processes in semi- or fully continuous mode with 500-1000L bioreactors. The processes can be tailored to provide the required amount of drug substance by simply adjusting the process duration and, if necessary, applying scaling-out (operating multiple manufacturing trains at the same scale) instead of using a traditional but more challenging scale-up strategy based on increasing the size of the bioreactor.
Our goal: Achieving greater cost-efficiency for commercial supply
Read the full article recently published in the BioProcess Int. ebook May 2022 about ‘Continuous Processing’